Overview
NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma. This is because Wyeth did not provide an evidence submission.
Last reviewed: 27 October 2010
Next review: We will review this decision if the company decides to make a submission.